Condition: Solid Tumor · Rhabdomyosarcoma · Sponsor: University of Texas Southwestern Medical Center
This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
This description comes directly from the study's public registry record.
Arhanti Sadanand, MD · 214-645-9122 · Arhanti.Sadanand@UTSouthwestern.edu
Sara Runyan · 214-648-7146 · sara.runyan@utsouthwestern.edu
Always discuss trial participation with your own doctor first.
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
| Cincinnati Children's Hospital | Cincinnati, Ohio, United States | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| The University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| Texas Children's Hospital | Houston, Texas, United States | Recruiting |
| Seattle Children's | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04796012